0001640455-20-000070.txt : 20200629
0001640455-20-000070.hdr.sgml : 20200629
20200629193107
ACCESSION NUMBER: 0001640455-20-000070
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200626
FILED AS OF DATE: 20200629
DATE AS OF CHANGE: 20200629
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Higgons John Duncan
CENTRAL INDEX KEY: 0001581954
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37998
FILM NUMBER: 20999013
MAIL ADDRESS:
STREET 1: C/O AGIOS PHARMACEUTICALS, INC.
STREET 2: 38 SIDNEY STREET, 2ND FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Jounce Therapeutics, Inc.
CENTRAL INDEX KEY: 0001640455
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 454870634
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 780 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 857-259-3840
MAIL ADDRESS:
STREET 1: 780 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
wf-form4_159347344629653.xml
FORM 4
X0306
4
2020-06-26
0
0001640455
Jounce Therapeutics, Inc.
JNCE
0001581954
Higgons John Duncan
C/O JOUNCE THERAPEUTICS, INC.
780 MEMORIAL DRIVE
CAMBRIDGE
MA
02139
1
0
0
0
Stock Option (Right to Buy)
7.58
2020-06-26
4
A
0
13550
0
A
2030-06-26
Common Stock
13550.0
13550
D
The option will vest in equal quarterly installments during the four quarters following the grant date, provided that if the Issuer's 2021 annual meeting of stockholders occurs before the one-year anniversary of the grant date, the unvested portion of the option will vest as of the date of such annual meeting, subject in each case to the Reporting Person's continued service on the Issuer's board of directors.
/s/ Kim C. Drapkin, Attorney-in-Fact
2020-06-29